A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations
Abstract
Authors
J.J. Carlson J.F. Slejko H. Goertz D.L. Veenstra